Biocon Ltd.
BIOCONHealthcare filings
We hold this company’s filings and have not read the financial statements out of them yet. Every filing on record is listed under filings, and each one opens.
Earnings calls
15 transcript(s)/analyst meet(s) served; 0 document(s) on file are not transcripts (cover letters, duplicates, unresolved) and are excluded. Speaker attribution is shown only where the segmenter attributes ≥ 95% of sentences to management or analysts (0 of 15 documents here); elsewhere sentences render unattributed.
| Kind | Date | Period | Served | Attribution rate |
|---|---|---|---|---|
| TRANSCRIPT | 20220506 | 2022-03-31 | yes | |
| TRANSCRIPT | 20220803 | 2022-06-30 | yes | |
| TRANSCRIPT | 20221122 | 2022-09-30 | yes | |
| TRANSCRIPT | 20230222 | 2022-12-31 | yes | |
| TRANSCRIPT | 20230531 | 2023-03-31 | yes | |
| TRANSCRIPT | 20230821 | 2023-06-30 | yes | |
| TRANSCRIPT | 20231120 | 2023-09-30 | yes | |
| TRANSCRIPT | 20240216 | 2023-12-31 | yes | |
| TRANSCRIPT | 20240523 | 2024-03-31 | yes | |
| TRANSCRIPT | 20240819 | 2024-06-30 | yes | |
| TRANSCRIPT | 20241107 | 2024-09-30 | yes | |
| TRANSCRIPT | 20250207 | 2024-12-31 | yes | |
| TRANSCRIPT | 20260217 | 2025-12-31 | yes | |
| TRANSCRIPT | 20260514 | 2026-03-31 | yes | |
| TRANSCRIPT | 20260811 | 2026-06-30 | yes |
BIOCON
files the standard Schedule III statements. Every figure below opens to the filing it was read from; where a figure is not shown, the reason is printed in its place.
Identity
| Statement division | general |
| Scope served | consolidated |
| Panels on this page | 4 |
Market
The closes are adjusted for every split and bonus on record inside the period this series covers, and each adjustment is checked against the price move on its ex-date.
| Last close | 387.00 |
| 52-week range | 338.9 – 440.7 |
| Return 1M | -7.24% |
| Return 3M | -7.0% |
| Return 1Y | 7.81% |
| Return 3Y | 46.54% |
| Return 5Y | 7.46% |
| Market capitalisation | not shown — we could not confirm it |
| Shares outstanding | not shown — we could not confirm it |
| P/E | not shown — we could not confirm it |
| P/B | not shown — we could not confirm it |
| EV/EBITDA | not shown — we could not confirm it |
Latest quarter filed — period ending 2026-06-30
In INR crore except per-share figures. `period_id` is the period the filing names for the number; the date beside each cell is when it was filed.
| Revenue from operations | 4,336.00 |
| Other income | 54.00 |
| Total income | 4,390.00 |
| Cost of materials consumed | 1,424.00 |
| Purchases of stock-in-trade | 382.00 |
| Changes in inventories | -338.00 |
| Employee benefit expense | 916.00 |
| Finance costs | 213.00 |
Ownership — 2026-06-30, and the change from 2026-06-29
| Holder | Per cent | Change |
|---|---|---|
| promoter and promoter group | 0.45 | 0.00 |
| institutions foreign | 0.08 | -0.00 |
| institutions domestic | 0.23 | 0.00 |
| mutual funds | 0.15 | -0.00 |
| public | 0.55 | 0.00 |
Documents on file
| Class | Most recent | On file |
|---|---|---|
| TRANSCRIPT | 2026-06-30 | 15 |
Financial statements
Filed results, consolidated, in INR crore except per-share figures. Every figure opens to the filing it was read from. Quarterly and annual columns are the periods the filing itself names, never a document date.
Quarterly results, as filed
| Line | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 2,320.00 | 2,941.00 | 3,774.00 | 3,423.00 | 3,462.00 | 3,954.00 | 3,917.00 | 3,433.00 | 3,590.00 | 3,821.00 | 4,417.00 | 3,942.00 | 4,296.00 | 4,173.00 | 4,517.00 | 4,336.00 |
| Other income | 64.00 | 79.00 | 155.00 | 94.00 | 158.00 | 566.00 | 49.00 | 1,134.00 | 32.00 | 35.00 | 37.00 | 80.00 | 93.00 | 117.00 | 52.00 | 54.00 |
| Total income | 2,384.00 | 3,020.00 | 3,929.00 | 3,516.00 | 3,620.00 | 4,519.00 | 3,966.00 | 4,567.00 | 3,623.00 | 3,856.00 | 4,454.00 | 4,022.00 | 4,388.00 | 4,290.00 | 4,569.00 | 4,390.00 |
| Cost of materials consumed | 958.00 | 1,074.00 | 414.00 | 1,026.00 | 1,166.00 | 1,402.00 | 1,478.00 | 860.00 | 1,009.00 | 1,293.00 | 1,114.00 | 1,224.00 | 1,368.00 | 1,327.00 | 1,359.00 | 1,424.00 |
| Purchases of stock-in-trade | 70.00 | 37.00 | 502.00 | 278.00 | 372.00 | 33.00 | -0.00 | 408.00 | 49.00 | 86.00 | 84.00 | 837.00 | 135.00 | 168.00 | 223.00 | 382.00 |
| Changes in inventories | -276.00 | -131.00 | 312.00 | -94.00 | -411.00 | -204.00 | -148.00 | -86.00 | 124.00 | -19.00 | 275.00 | -656.00 | 44.00 | -156.00 | -182.00 | -338.00 |
| Employee benefit expense | 540.00 | 559.00 | 569.00 | 579.00 | 622.00 | 721.00 | 742.00 | 755.00 | 790.00 | 788.00 | 811.00 | 833.00 | 888.00 | 875.00 | 912.00 | 916.00 |
| Finance costs | 30.00 | 120.00 | 249.00 | 233.00 | 248.00 | 267.00 | 227.00 | 236.00 | 226.00 | 223.00 | 212.00 | 277.00 | 272.00 | 210.00 | 232.00 | 213.00 |
| Depreciation and amortisation | 231.00 | 301.00 | 364.00 | 358.00 | 389.00 | 414.00 | 407.00 | 405.00 | 420.00 | 425.00 | 436.00 | 455.00 | 473.00 | 515.00 | 513.00 | 547.00 |
| Other expenses | 557.00 | 758.00 | 978.00 | 919.00 | 971.00 | 1,074.00 | 930.00 | 874.00 | 933.00 | 922.00 | 1,055.00 | 955.00 | 1,025.00 | 1,125.00 | 1,185.00 | 1,105.00 |
| Total expenses | 2,110.00 | 2,718.00 | 3,389.00 | 3,299.00 | 3,358.00 | 3,708.00 | 3,635.00 | 3,454.00 | 3,550.00 | 3,718.00 | 3,988.00 | 3,925.00 | 4,205.00 | 4,065.00 | 4,241.00 | 4,249.00 |
| Profit before exceptional items and tax | 274.00 | 302.00 | 540.00 | 217.00 | 262.00 | 811.00 | 330.00 | 1,114.00 | 72.00 | 138.00 | 466.00 | 97.00 | 183.00 | 226.00 | 328.00 | 141.00 |
| Exceptional items | -17.00 | -271.00 | -3.00 | 0.00 | -24.00 | 21.00 | -9.00 | 32.00 | 26.00 | 18.00 | 20.00 | 0.00 | -12.00 | -293.00 | -80.00 | -14.00 |
| Profit before tax | 257.00 | 30.00 | 537.00 | 217.00 | 238.00 | 832.00 | 322.00 | 1,146.00 | 98.00 | 156.00 | 487.00 | 97.00 | 171.00 | -68.00 | 248.00 | 128.00 |
| Current tax | 147.00 | -5.00 | 82.00 | 43.00 | 52.00 | 83.00 | 136.00 | 225.00 | 24.00 | 114.00 | 6.00 | 67.00 | 59.00 | 67.00 | 251.00 | 116.00 |
| Deferred tax | 0.00 | 0.00 | 0.00 | -9.00 | -11.00 | -28.00 | -40.00 | 58.00 | 47.00 | -39.00 | 21.00 | -59.00 | -21.00 | -83.00 | -202.00 | -125.00 |
| Tax expense | 147.00 | -5.00 | 82.00 | 35.00 | 42.00 | 55.00 | 96.00 | 284.00 | 71.00 | 75.00 | 27.00 | 8.00 | 38.00 | -16.00 | 49.00 | -9.00 |
| Profit for the period | 82.00 | -21.00 | 414.00 | 149.00 | 173.00 | 753.00 | 223.00 | 862.00 | 27.00 | 81.00 | 459.00 | 89.00 | 133.00 | -52.00 | 199.00 | 137.00 |
| Profit attributable to owners | 47.00 | -42.00 | 313.00 | 101.00 | 126.00 | 660.00 | 136.00 | 660.00 | -16.00 | 25.00 | 344.00 | 31.00 | 84.00 | 144.00 | 126.00 | 141.00 |
| Profit attributable to non-controlling interests | 35.00 | 21.00 | 101.00 | 48.00 | 47.00 | 93.00 | 87.00 | 202.00 | 43.00 | 56.00 | 115.00 | 58.00 | 48.00 | -196.00 | 73.00 | -4.00 |
| Other comprehensive income | 18.00 | 190.00 | -66.00 | 171.00 | 190.00 | 43.00 | -17.00 | 42.00 | 522.00 | 57.00 | -184.00 | -206.00 | 970.00 | 306.00 | 974.00 | 789.00 |
| Total comprehensive income | 100.00 | 169.00 | 349.00 | 320.00 | 363.00 | 796.00 | 206.00 | 903.00 | 549.00 | 138.00 | 276.00 | -116.00 | 1,103.00 | 254.00 | 1,173.00 | 926.00 |
| Earnings per share, basic | 0.39 | -0.35 | 2.62 | 0.85 | 1.05 | 5.52 | 1.13 | 5.51 | -0.13 | 0.21 | 2.88 | 0.26 | 0.66 | 1.08 | 0.79 | 0.87 |
| Earnings per share, diluted | 0.39 | -0.35 | 2.62 | 0.85 | 1.05 | 5.51 | 1.13 | 5.51 | -0.13 | 0.21 | 2.87 | 0.26 | 0.65 | 1.07 | 0.79 | 0.87 |
Annual results, as filed
| Line | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 5,514.00 | 6,367.00 | 7,106.00 | 8,184.00 | 11,174.00 | 14,756.00 | 15,262.00 | 16,927.00 |
| Other income | 144.00 | 161.00 | 254.00 | 213.00 | 376.00 | 866.00 | 1,208.00 | 342.00 |
| Total income | 5,659.00 | 6,529.00 | 7,360.00 | 8,397.00 | 11,550.00 | 15,621.00 | 16,470.00 | 17,270.00 |
| Cost of materials consumed | 1,980.00 | 2,168.00 | 2,430.00 | 2,814.00 | 3,191.00 | 5,072.00 | 4,277.00 | 5,278.00 |
| Purchases of stock-in-trade | 127.00 | 85.00 | 68.00 | 161.00 | 626.00 | 683.00 | 627.00 | 1,363.00 |
| Changes in inventories | -210.00 | -201.00 | -290.00 | -257.00 | -154.00 | -857.00 | 294.00 | -950.00 |
| Employee benefit expense | 1,165.00 | 1,459.00 | 1,741.00 | 1,880.00 | 2,181.00 | 2,664.00 | 3,144.00 | 3,508.00 |
| Finance costs | 71.00 | 65.00 | 58.00 | 68.00 | 419.00 | 974.00 | 897.00 | 990.00 |
| Depreciation and amortisation | 448.00 | 552.00 | 715.00 | 814.00 | 1,113.00 | 1,569.00 | 1,687.00 | 1,957.00 |
| Other expenses | 1,059.00 | 1,253.00 | 1,504.00 | 1,615.00 | 2,818.00 | 3,895.00 | 3,754.00 | 4,273.00 |
| Total expenses | 4,639.00 | 5,381.00 | 6,226.00 | 7,096.00 | 10,195.00 | 14,000.00 | 14,680.00 | 16,419.00 |
| Profit before exceptional items and tax | 1,019.00 | 1,147.00 | 1,134.00 | 1,301.00 | 1,356.00 | 1,621.00 | 1,790.00 | 851.00 |
| Exceptional items | 195.00 | 68.00 | 13.00 | -111.00 | -291.00 | -12.00 | 96.00 | -403.00 |
| Profit before tax | 1,214.00 | 1,215.00 | 1,147.00 | 1,190.00 | 1,064.00 | 1,609.00 | 1,887.00 | 448.00 |
| Current tax | 204.00 | 315.00 | 222.00 | 212.00 | 254.00 | 314.00 | 369.00 | 444.00 |
| Deferred tax | 8.00 | 0.00 | 0.00 | 0.00 | 0.00 | -87.00 | 88.00 | -364.00 |
| Tax expense | 212.00 | 315.00 | 222.00 | 212.00 | 254.00 | 227.00 | 457.00 | 79.00 |
| Profit for the period | 1,003.00 | 871.00 | 846.00 | 772.00 | 643.00 | 1,298.00 | 1,429.00 | 369.00 |
| Profit attributable to owners | 905.00 | 748.00 | 740.00 | 648.00 | 463.00 | 1,022.00 | 1,013.00 | 386.00 |
| Profit attributable to non-controlling interests | -97.00 | 123.00 | 106.00 | 123.00 | 180.00 | 275.00 | 416.00 | -17.00 |
| Other comprehensive income | -72.00 | -188.00 | 214.00 | 110.00 | 77.00 | 387.00 | 437.00 | 2,044.00 |
| Total comprehensive income | 930.00 | 682.00 | 1,061.00 | 882.00 | 720.00 | 1,684.00 | 1,866.00 | 2,413.00 |
| Earnings per share, basic | 15.30 | 6.32 | 6.24 | 5.44 | 3.88 | 8.55 | 8.46 | 2.82 |
| Earnings per share, diluted | 15.20 | 6.30 | 6.19 | 5.42 | 3.87 | 8.54 | 8.46 | 2.82 |
Balance sheet, as filed
| Line | 2022-09-30 | 2023-03-31 | 2023-09-30 | 2024-03-31 | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Total assets | 22,664.00 | 52,043.00 | 54,577.00 | 56,071.00 | 57,128.00 | 58,797.00 | 62,760.00 | 63,651.00 |
| Non-current assets | 12,616.00 | 39,709.00 | 40,507.00 | 40,892.00 | 41,974.00 | 42,511.00 | 43,979.00 | 46,471.00 |
| Current assets | 10,048.00 | 12,334.00 | 14,070.00 | 15,179.00 | 15,154.00 | 16,286.00 | 18,781.00 | 17,180.00 |
| Property, plant and equipment | 7,171.00 | 7,535.00 | 7,662.00 | 7,418.00 | 7,462.00 | 8,708.00 | 8,865.00 | 9,473.00 |
| Capital work-in-progress | 2,275.00 | 2,588.00 | 3,260.00 | 3,985.00 | 4,354.00 | 4,102.00 | 4,651.00 | 4,613.00 |
| Goodwill | 26.00 | 16,136.00 | 16,334.00 | 16,372.00 | 16,467.00 | 16,786.00 | 17,460.00 | 18,378.00 |
| Other intangible assets | 837.00 | 5,796.00 | 6,473.00 | 6,853.00 | 6,661.00 | 6,469.00 | 7,049.00 | 8,636.00 |
| Inventories | 2,982.00 | 4,244.00 | 4,911.00 | 4,944.00 | 4,965.00 | 4,931.00 | 5,777.00 | 6,086.00 |
| Trade receivables | 2,079.00 | 3,573.00 | 4,033.00 | 6,231.00 | 6,129.00 | 5,488.00 | 5,519.00 | 5,987.00 |
| Cash and cash equivalents | 751.00 | 1,324.00 | 644.00 | 1,234.00 | 1,688.00 | 3,227.00 | 4,275.00 | 2,416.00 |
| Total equity and liabilities | 22,664.00 | 52,043.00 | 54,577.00 | 56,071.00 | 57,128.00 | 58,797.00 | 62,760.00 | 63,651.00 |
| Equity | 10,840.00 | 22,489.00 | 24,277.00 | 25,275.00 | 26,720.00 | 27,712.00 | 33,055.00 | 36,622.00 |
| Equity share capital | 600.00 | 600.00 | 600.00 | 600.00 | 600.00 | 600.00 | 668.00 | 810.00 |
| Other equity | 9,028.00 | 17,267.00 | 18,382.00 | 19,183.00 | 20,393.00 | 21,044.00 | 26,135.00 | 33,221.00 |
| Total liabilities | 11,824.00 | 29,554.00 | 30,300.00 | 30,796.00 | 30,408.00 | 31,085.00 | 29,705.00 | 27,029.00 |
| Non-current liabilities | 7,699.00 | 21,043.00 | 19,933.00 | 15,437.00 | 14,603.00 | 16,751.00 | 13,450.00 | 12,960.00 |
| Current liabilities | 4,125.00 | 8,511.00 | 10,366.00 | 15,359.00 | 15,805.00 | 14,334.00 | 16,254.00 | 14,069.00 |
| Borrowings, non-current | 4,438.00 | 15,290.00 | 15,007.00 | 12,932.00 | 11,982.00 | 12,405.00 | 10,570.00 | 10,746.00 |
| Borrowings, current | 1,178.00 | 2,480.00 | 2,816.00 | 2,797.00 | 4,168.00 | 5,350.00 | 5,338.00 | 4,078.00 |
| Trade payables | 1,699.00 | 3,983.00 | 4,392.00 | 6,272.00 | 6,369.00 | 6,549.00 | 6,976.00 | 6,772.00 |
Cash flow, as filed
| Line | 2022-09-30 | 2023-03-31 | 2023-09-30 | 2024-03-31 | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Net cash from operating activities | 303.00 | 1,852.00 | -378.00 | 2,954.00 | 705.00 | 4,061.00 | 803.00 | 1,994.00 |
| Net cash from investing activities | -1,674.00 | -14,282.00 | -995.00 | -1,004.00 | 966.00 | -234.00 | -1,276.00 | -2,082.00 |
| Net cash from financing activities | 1,431.00 | 13,049.00 | 488.00 | -2,333.00 | -1,279.00 | -1,854.00 | 1,403.00 | -924.00 |
| Purchase of property, plant and equipment | 790.00 | 1,596.00 | 837.00 | 1,680.00 | 794.00 | 2,137.00 | 861.00 | 1,798.00 |
| Net increase in cash | 83.00 | 641.00 | -895.00 | -380.00 | 403.00 | 2,004.00 | 1,047.00 | -812.00 |
| con:CFO.BEFORE_TAX | 403.00 | 2,081.00 | -268.00 | 3,408.00 | 1,059.00 | 4,521.00 | 901.00 | 2,237.00 |
| con:INTEREST_RECEIVED.OPERATING | 0.00 | 0.00 | 0.00 | -161.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INTEREST_PAID.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 353.00 | 0.00 | 0.00 | 0.00 |
| con:DIVIDENDS_RECEIVED.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:TAX_PAID.OPERATING | 100.00 | 229.00 | 110.00 | 292.00 | 0.00 | 460.00 | 98.00 | 243.00 |
| con:CF_OTHER.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INVESTMENTS_PURCHASED | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INVESTMENTS_SOLD | 0.00 | 3,447.00 | 0.00 | 0.00 | 1,142.00 | 1,825.00 | 0.00 | 0.00 |
| con:PPE_DISPOSALS | 3.00 | 3.00 | 2.00 | 23.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.SUBSIDIARIES_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.SUBSIDIARIES_ACQUIRED | 0.00 | 0.00 | 0.00 | 553.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.JV_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.JV_ACQUIRED | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Who owns it
The shareholding pattern filed with the exchange every quarter, as a series. Percentages are of total shares. Each figure names the filing it was read from and the date it was filed.
| Holder | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-19 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-01-05 | 2026-01-14 | 2026-03-31 | 2026-06-29 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter and promoter group | 60.64 | 60.64 | 60.64 | 60.64 | 60.64 | 54.45 | 54.45 | 0.54 | 0.54 | 0.48 | 0.45 | 0.45 | 0.45 | 0.45 |
| Domestic institutions | 13.68 | 14.30 | 14.44 | 15.37 | 15.72 | 21.45 | 22.82 | 0.22 | 0.22 | 0.20 | 0.24 | 0.24 | 0.23 | 0.23 |
| Mutual funds | — | — | — | — | — | — | 15.24 | 0.14 | 0.14 | 0.12 | 0.17 | 0.17 | 0.15 | 0.15 |
| Insurance companies | 5.01 | 5.51 | 6.23 | 6.43 | 6.55 | 5.68 | 6.79 | 0.07 | 0.07 | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 |
| Foreign institutions | 5.63 | 5.90 | 5.93 | 5.66 | 5.66 | 7.00 | 6.04 | 0.07 | 0.07 | 0.07 | 0.07 | 0.08 | 0.08 | 0.08 |
| Government | — | — | — | — | — | — | — | — | 0.00 | — | 0.00 | — | — | — |
| Public | 39.05 | 39.08 | 39.12 | 39.14 | 39.15 | 45.37 | 45.37 | 0.45 | 0.45 | 0.52 | 0.55 | 0.55 | 0.55 | 0.55 |
| Non-institutional | 19.73 | 18.89 | 18.75 | 18.12 | 17.76 | 16.91 | 16.50 | 0.17 | 0.16 | 0.25 | 0.24 | 0.23 | 0.24 | 0.24 |
| Shares outstanding | 1200600000 | 1200600000 | 1200600000 | 1200600000 | 1200600000 | 1336963635 | 1336963635 | 1336963635 | 1336963635 | 1508243188 | 1620907773 | 1620907773 | 1629694135 | 1629694135 |
Related parties
Transactions with related parties as disclosed to the exchange for the period ending 2024-09-30, by counterparty, largest first. Amounts are as filed. Each row names the filing and the date it was filed.
| Counterparty | Relationship | Type | Amount in the period | Transactions |
|---|---|---|---|---|
| Biocon Biologics Inc | Step down subsidiary | Purchase of goods or services, Sale of goods or serv | 13,694,170,000.00 | 8 |
| Biosimilars NewCo Limited | Wholly owned subsidiary | Any other transaction, Purchase of goods or services | 13,672,230,000.00 | 12 |
| Biocon Biologics Limited | Subsidiary | Any other transaction, Interest received, Investment | 8,219,770,000.00 | 24 |
| Biocon Biologics UK Limited | Step down subsidiary | Any other transaction, Sale of goods or services | 5,715,490,000.00 | 7 |
| Biosimilar Collaborations Ireland Limited | Wholly owned subsidiary | Any other transaction, Purchase of goods or services | 4,884,310,000.00 | 6 |
| Biocon Biologics France SAS | Fellow subsidiary | Purchase of goods or services, Sale of goods or serv | 3,187,110,000.00 | 3 |
| Biocon Pharma Inc | Wholly owned subsidiary | Any other transaction, Purchase of goods or services | 2,612,080,000.00 | 10 |
| Biocon Pharma Limited | Wholly owned subsidiary | Any other transaction, Sale of goods or services | 1,951,480,000.00 | 10 |
| Biocon Generics Inc | Wholly owned subsidiary | Any other transaction, Interest received, Investment | 1,906,330,000.00 | 12 |
| Biocon Biosphere Limited | Wholly owned subsidiary | Any other transaction, Interest received, Loan, Purc | 1,718,080,000.00 | 12 |
| Biosimilars Newco Limited | Fellow subsidiary | Any other transaction, Purchase of goods or services | 1,563,440,000.00 | 4 |
| Biocon Biologics Germany GmbH | Fellow subsidiary | Purchase of goods or services | 1,027,690,000.00 | 3 |
| Biocon SDN BHD | Step down subsidiary | Any other transaction, Purchase of goods or services | 953,880,000.00 | 11 |
| Biocon Biologics Canada Inc | Step down subsidiary | Purchase of goods or services, Sale of goods or serv | 827,520,000.00 | 6 |
| Bicara Therapeutics Inc | Enterprise in which a director of | Any other transaction, Sale of goods or services | 576,310,000.00 | 3 |
What management said
Every earnings call we hold for this company, read in full. Prepared remarks are separated from the question-and-answer session and every paragraph names who said it and on which page. These are management’s own words, not filed figures.
| Date | Quarter | Who spoke | |
|---|---|---|---|
| 2026-08-11 | Q1FY27 | Read the call | |
| 2026-05-14 | Q4FY26 | Read the call | |
| 2026-02-17 | Q3FY26 | Read the call |
Some earlier announcements under this heading are covering letters only — no transcript was attached.
What they said about it, quarter by quarter
| Topic | Q1FY27 | Q3FY26 | Q4FY26 |
|---|---|---|---|
| Capex | First, if you can update on utilization of some of the new units, including unit in the US and what kind of cost drag you are incurring as these new p… | I think we mentioned about capex being largely behind, and a lot of the focus now on cash flow generation. | So, as you mentioned, you are done with majority of investment in capex, etc., and focus ahead will be on cash generation. |
| Capital allocation | — | And our strategy typically in India is through a partner, since we had divested our business, the branded formulations business to Eris, we did tie up… | — |
| Costs | They bring cost savings to the United States, and it should continue to be bipartisan between the Democrats and the Republicans to save costs to the A… | — | — |
| Debt and cash | My question pertains to debt and working capital. | So Kedar, can you also update us on the net debt position as of December 31 or as of, say, current? | And Kedar, how should we think about deleveraging in fiscal '27 now that Biocon -- the merger Biocon Biologics is done? |
| Demand | Apart from that, insulins are tracking very well and very robustly, and with the commissioning and approval of the second drug product line in Malaysi… | We're also seeing a very substantial demand for our products across the U.S. and in Europe. | So, what kind of visibility we have in terms of higher demand or like your capability to supply this product to gain meaningful market share from here… |
| Guidance | So that's really the way I would guide you to look at the Biocon business and not just jump to conclusions that because one part of a small business i… | In fact, you will see that those margins have been higher than what our guidance has been in the mid-20s. | Shreehas, I understand you don't want to give specific guidance, but if I were to think about fourth quarter FY '27 exit run rate, given the launches … |
| Margin | We focused on getting cost out of the system that's helped as well and operating leverage has started to play. | And as we focused on this current quarter, which you saw in our financials, we were able to also, given that we had a good demand for our products, pr… | Operating leverage is starting to kick in, which you'll see flow through in the first quarter that will come out, you will start seeing it. |
| People | So, I think all these three levers are helping, and you know there'll be some time lag before the new units start contributing meaningfully in terms o… | — | Just on the biosimilars, what could be the capacity utilization currently? |
| Pricing | One is some of the premium on API products, pricing premium; secondly, optimization of the R&D portfolio; and thirdly, opex. | So, I think what we have heard other companies that, of course, there have been approvals and they're going to launch the product soon, and the pricin… | — |
| Revenue growth | And then obviously the growing top line will contribute towards the leverage benefit. | And the growth of that particular line will be lower than the revenue growth. | So, there's a sequential growth of 12% that you are seeing on a rupee basis in the revenues. |